Cyclophosphamide is an antineoplastic alkylating agent, used in the treatment of many cancers.

### INN
Cyclophosphamide

### ATC codes
L01AA01

### Medicine type
Chemical agent

### EML status history
- First added in 1977 (TRS 615) for Diffuse large B-cell lymphomas
- Added in 1977 (TRS 615) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma
- Added in 1977 (TRS 615) for Malignant neoplasms of breast
- Added in 1977 (TRS 615) for Malignant trophoblastic neoplasms of placenta
- Added in 1977 (TRS 615) for Follicular lymphoma
- Added in 1977 (TRS 615) for Other specified malignant neoplasms of breast
- Added in 1977 (TRS 615) for Hodgkin lymphoma
- Added in 1977 (TRS 615) for Rhabdomyosarcoma primary site
- Added in 1977 (TRS 615) for Burkitt lymphoma including Burkitt leukaemia
- Added in 1977 (TRS 615) for Lymphoid leukaemia, not elsewhere classified
- Added in 1977 (TRS 615) for Ewing sarcoma of bone and articular cartilage of unspecified sites
- Added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 2019 (TRS 1021) for Plasma cell myeloma
- Added in 2021 (TRS 1035) for Other specified gliomas of brain
- Added in 2021 (TRS 1035) for Malignant neoplasms of kidney, except renal pelvis
- Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive
- Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative

### Recommendations

- **INN**
  - Cyclophosphamide
- **ATC codes**
  - L01AA01
- **Medicine type**
  - Chemical agent
- **EML status history**
  - First added in 1977 (TRS 615) for Diffuse large B-cell lymphomas
  - Added in 1977 (TRS 615) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma
  - Added in 1977 (TRS 615) for Malignant neoplasms of breast
  - Added in 1977 (TRS 615) for Malignant trophoblastic neoplasms of placenta
  - Added in 1977 (TRS 615) for Follicular lymphoma
  - Added in 1977 (TRS 615) for Other specified malignant neoplasms of breast
  - Added in 1977 (TRS 615) for Hodgkin lymphoma
  - Added in 1977 (TRS 615) for Rhabdomyosarcoma primary site
  - Added in 1977 (TRS 615) for Burkitt lymphoma including Burkitt leukaemia
  - Added in 1977 (TRS 615) for Lymphoid leukaemia, not elsewhere classified
  - Added in 1977 (TRS 615) for Ewing sarcoma of bone and articular cartilage of unspecified sites
  - Added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites
  - Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites
  - Added in 2019 (TRS 1021) for Plasma cell myeloma
  - Added in 2021 (TRS 1035) for Other specified gliomas of brain
  - Added in 2021 (TRS 1035) for Malignant neoplasms of kidney, except renal pelvis
  - Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive
  - Added in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative

- **Wikipedia**
  - Cyclophosphamide

- **DrugBank**
  - Cyclophosphamide
Cytotoxic medicines

Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
Oral > Solid: 25 mg; 50 mg
Oral > Solid: 25 mg tablet
Parenteral > General injections > unspecified: 500 mg in vial powder for injection
Oral > Solid: 25 mg; 50 mg tablet

Indications

Diffuse large B-cell lymphomas
Chronic lymphocytic leukaemia or small lymphocytic lymphoma
Malignant neoplasms of breast
Malignant trophoblastic neoplasms of placenta
Follicular lymphoma
Other specified malignant neoplasms of breast
Hodgkin lymphoma
Rhabdomyosarcoma primary site
Ewing sarcoma of bone and articular cartilage of unspecified sites
Lymphoid leukaemia, not elsewhere classified
Burkitt lymphoma including Burkitt leukaemia
Unspecified malignant neoplasms of ill-defined or unspecified sites
Plasma cell myeloma
Other specified gliomas of brain
Malignant neoplasms of kidney, except renal pelvis
Anaplastic large cell lymphoma, ALK-positive
Anaplastic large cell lymphoma, ALK-negative